title: Near-infrared mediated quantum dots and paclitaxel co-loaded nanostructured lipid carriers for cancer theragnostic.
abstract: Timing is an important factor in cancer management. Theragnostic systems have benefit of improving patients' life-quality by expediting therapeutic decisions. The objective of this study was to explore the potential of co-loaded [quantum dots (CdTe/CdS/ZnS) and paclitaxel] NLC (nanostructured lipid carriers) as a parenteral multifunctional delivery system. The co-loaded NLC was prepared by emulsion-evaporation and low temperature-solidification method utilising glyceryl monostearate, oleic acid, and soya phosphatidylcholine as lipid matrix. In characterising the co-loaded NLC, physicochemical properties of particle size, polydispersity index (PDI), zeta potential (ZP), morphology, encapsulation efficacy (EE) and drug loading (DL) were investigated. Moreover, in-vitro paclitaxel release profile, cytotoxicity, histopathological, in-vivo anti-tumour efficacy, and in-vivo and ex-vivo fluorescence optical imaging abilities of the co-loaded NLC were assessed. The mean particle size, PDI and ZP were reported to be 115.93±1.61nm, 0.17±0.04 and -0.22±0.03mV, respectively. The particles were spheroid-like in shape with relatively smooth surface. A higher EE (80.70±2.11%) and DL (4.68±0.04%) were recorded. The coloaded NLC exhibited a biphasic pattern of drug release. IC50value was found to be 1.05±0.58μM. The tumour growth inhibition rate of 77.85% was registered. The in-vivo and ex-vivo imaging results indicated capability of the co-loaded NLC to specifically target and detect the H22 tumour. Tissues showed no significant cytoarchitectural differences. We can satisfactorily conclude that co-loaded NLC formulation can be qualified as a splendid parenteral drug delivery system foundation for cancer theragnostic.
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: liveseyus@yahoo.co.uk.
authors.forename: Livesey David
authors.initials: LD
authors.lastname: Olerile
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: liuyongjun@sdu.edu.cn.
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Liu
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: bozh315@163.com.
authors.forename: Bo
authors.initials: B
authors.lastname: Zhang
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: wangtianqi1990@hotmail.com.
authors.forename: Tianqi
authors.initials: T
authors.lastname: Wang
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: shengjun0402@163.com.
authors.forename: Shengjun
authors.initials: S
authors.lastname: Mu
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: zhangjing002015@163.com.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Institute of Social Medicine and Health Administration, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: tshepisokgetse@gmail.com.
authors.forename: Lesego
authors.initials: L
authors.lastname: Selotlegeng
authors.affiliation: The School of Pharmaceutical Sciences, Shandong University, 44 Wenhua Xi Road, Jinan 250012, China. Electronic address: zhangnancy9@sdu.edu.cn.
authors.forename: Na
authors.initials: N
authors.lastname: Zhang
mesh_terms: D000818:Animals; D004337:Drug Carriers / Q000737:chemistry; D016503:Drug Delivery Systems; D004655:Emulsions; D005260:Female; D005989:Glycerides / Q000737:chemistry; D056945:Hep G2 Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D008055:Lipids / Q000737:chemistry*; D051379:Mice; D008856:Microscopy, Fluorescence; D049329:Nanostructures; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy*; D019301:Oleic Acid / Q000737:chemistry; D055095:Optics and Photonics; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry*; D010316:Particle Size; D010713:Phosphatidylcholines / Q000737:chemistry; D045663:Quantum Dots; D019265:Spectroscopy, Near-Infrared; D013696:Temperature; D000068936:Theranostic Nanomedicine
chemical_list: D004337:Drug Carriers; D004655:Emulsions; D005989:Glycerides; D008055:Lipids; D010713:Phosphatidylcholines; C048159:glyceryl monostearate; D019301:Oleic Acid; D017239:Paclitaxel
keywords: Cancer theragnostic; Co-loaded NLC; Multifunctional; Paclitaxel; Parenteral delivery system; Quantum dots